FIA
CATX icon

FNY Investment Advisers’s Perspective Therapeutics CATX Stock Holding History

FNY Investment Advisers’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-60
Closed – – 724
2022
Q1 		$0 Sell
60
-21
-26% -$77 ﹤0.01% 753
2021
Q4 		$0 Hold
81
– – ﹤0.01% 581
2021
Q3 		$0 Hold
81
– – ﹤0.01% 722
2021
Q2 		$0 Hold
81
– – ﹤0.01% 792
2021
Q1 		$0 Buy
+81
New +$1.22K ﹤0.01% 806

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TMWM
Taylor & Morgan Wealth Management Flint, Michigan $203M AUM 24.74% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Venator Capital Management Toronto, Ontario, Canada $48.7M AUM 87.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Investment Advisers's CATX Position: Q2 2022 in Review

FNY Investment Advisers sold out of Perspective Therapeutics (CATX) in Q2 2022, closing a stake of 60 shares.

FNY Investment Advisers first reported a position in CATX in Q1 2021 and held it in 5 quarters. The position peaked at $0 in Q1 2022. 43 funds tracked by Wall St. Rank hold CATX as of Q2 2022.

  • FNY Investment Advisers reported no remaining Perspective Therapeutics position as of Q2 2022 after selling out during the quarter.
  • FNY Investment Advisers sold 60 Perspective Therapeutics shares in Q2 2022.
  • FNY Investment Advisers first reported a position in Perspective Therapeutics in Q1 2021 and held it in 5 quarters.
  • FNY Investment Advisers's Perspective Therapeutics position peaked at $0 in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2022.

Based on FNY Investment Advisers's 13F filing for Q2 2022, filed 12 Jul 2022.